Charles Blanke

Charles Blanke

Auto-generated profile, based on publicly available information

Charles Blanke

10SWOG Group Chair’s Office, Knight Cancer Institute, Portland, Oregon

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2008 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
CBCharles D. Blanke
Charles D. Blanke
CRCathryn Rankin
Cathryn Rankin
GDGeorge D. Demetri
George D. Demetri
CRChristopher W. Ryan
Christopher W. Ryan
MMMargaret von Mehren
Margaret von Mehren
EBErnest C. Borden
Ernest C. Borden
Purpose: To assess potential differences in progression-free or overall survival when imatinib mesylate is administered to patients with incurable gastrointestinal stromal tumors (GIST) at a standard dose (400 mg daily) versus a high dose (400 mg twice daily). Patients and Methods: Patients with metastatic or surgically unresectable GIST were eligible for this phase III open-label clinical trial. At registration, patients were randomly assigned to either standard or high-dose imatinib, with close interval follow-up. If objective progression occurred by Response Evaluation Criteria in Solid Tumors, patients on the standard-dose arm could reregister to the trial and receive the high-dose imatinib regimen. Results: Seven hundred forty-six patients with advanced GIST from 148 centers across the United States and Canada were enrolled onto this trial in 9 months. With a median follow-up of 4.5 years, median progression-free survival was 18 months for patients on the standard-dose arm, and 20 months for those receiving high-dose imatinib. Median overall survival was 55 and 51 months, respectively. There were no statistically significant differences in objective response rates, progression-free survival, or overall survival. After progression on standard-dose imatinib, 33% of patients who crossed over to the high-dose imatinib regimen achieved either an objective response or stable disease. There were more grade 3, 4, and 5 toxicities noted on the high-dose imatinib arm. Conclusion: This trial confirms the effectiveness of imatinib as primary systemic therapy for patients with incurable GIST but did not show any advantage to higher dose treatment. It appears reasonable to initiate therapy with 400 mg daily and to consider dose escalation on progression of disease.

1 February 2008 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
CBCharles D. Blanke
Charles D. Blanke
GDGeorge D. Demetri
George D. Demetri
MMMargaret von Mehren
Margaret von Mehren
MHMichael C. Heinrich
Michael C. Heinrich
BEBurton Eisenberg
Burton Eisenberg
HJHeikki Joensuu
Heikki Joensuu
Purpose: The outcome of patients diagnosed with advanced gastrointestinal stromal tumor (GIST) and treated long-term with imatinib mesylate is unknown. A previous report of a randomized phase II trial of imatinib mesylate in patients with incurable GIST detailed high response rates at both the 400 and the 600 mg/d dose levels. We conducted a long-term analysis of patients treated on the trial, including patients followed during an extension phase, to evaluate survival, patterns of failure, and potential prognostic factors, including tumor mutational status. Patients and Methods: Patients with advanced GIST were enrolled onto an open-label, multicenter trial and were randomly assigned (1:1) to receive imatinib 400 versus 600 mg/d. Data were prospectively collected on KIT mutational status, total tumor area, and other potential prognostic factors. Patients were followed for a median of 63 months. Results: One hundred forty-seven patients were enrolled: 73 were in arm A (imatinib 400 mg/d), and 74 were in arm B (imatinib 600 mg/d). Response rates, median progression-free survival, and median overall survival were essentially identical on both arms, and median survival was 57 months for all patients. Forty-one patients overall (28%) remained on the drug long-term. Female sex, the presence of an exon 11 mutation, and normal albumin and neutrophil levels were independently associated with better survival. Conclusion: Nearly 50% of patients with advanced GIST who were treated with imatinib mesylate survived for more than 5 years, regardless of a 400 or 600 mg/d starting dose.

24 August 2020 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
AWAnna Dorothea Wagner
Anna Dorothea Wagner
AGAxel Grothey
Axel Grothey
TAThierry André
Thierry André
JDJesse G Dixon
Jesse G Dixon
NWNorman Wolmark
Norman Wolmark
QSQian Shi
Qian Shi
Adjuvant chemotherapy is a standard treatment option for patients with stage III and high-risk stage II colon cancer. Sex is one of several factors responsible for the wide inter-patient variability in drug responses. Amalgamated data on the effect of sex on the toxicity of current standard adjuvant treatment for colorectal cancer are missing. The objective of our study was to compare incidence and severity of major toxicities of fluoropyrimidine- (5FU or capecitabine) based adjuvant chemotherapy, with or without oxaliplatin, between male and female patients after curative surgery for colon cancer. Adult patients enrolled in 27 relevant randomized trials included in the ACCENT (Adjuvant Colon Cancer End Points) database, a large, multi-group, international data repository containing individual patient data, were included. Comparisons were conducted using logistic regression models (stratified by study and treatment arm) within each type of adjuvant chemotherapy (5FU, FOLFOX, capecitabine, CAPOX, and FOLFIRI). The following major toxicities were compared (grade III or IV and grade I-IV, according to National Cancer Institute Common Terminology Criteria [NCI-CTC] criteria, regardless of attribution): nausea, vomiting, nausea or vomiting, stomatitis, diarrhea, leukopenia, neutropenia, thrombocytopenia, anemia, and neuropathy (in patients treated with oxaliplatin). Data from 34 640 patients were analyzed. Statistically significant and clinically relevant differences in the occurrence of grade III or IV nonhematological {especially nausea (5FU: odds ratio [OR] = 2.33, 95% confidence interval [CI] = 1.90 to 2.87, P < .001; FOLFOX: OR = 2.34, 95% CI = 1.76 to 3.11, P < .001), vomiting (5FU: OR = 2.38, 95% CI = 1.86 to 3.04, P < .001; FOLFOX: OR = 2.00, 95% CI = 1.50 to 2.66, P < .001; CAPOX: OR = 2.32, 95% CI = 1.55 to 3.46, P < .001), and diarrhea (5FU: OR = 1.35, 95% CI = 1.21 to 1.51, P < .001; FOLFOX: OR = 1.60, 95% CI = 1.35 to 1.90, P < .001; FOLFIRI: OR = 1.57, 95% CI = 1.25 to 1.97, P < .001)} as well as hematological toxicities (neutropenia [5FU: OR = 1.55, 95% CI = 1.37 to 1.76, P < .001; FOLFOX: OR = 1.96, 95% CI = 1.71 to 2.25, P < .001; FOLFIRI: OR = 2.01, 95% CI = 1.66 to 2.43, P < .001; capecitabine: OR = 4.07, 95% CI = 1.84 to 8.99, P < .001] and leukopenia [5FU: OR = 1.74, 95% CI = 1.40 to 2.17, P < .001; FOLFIRI: OR = 1.75, 95% CI = 1.28 to 2.40, P < .001]) were observed, with women being consistently at increased risk. Our analysis confirms that women with colon cancer receiving adjuvant fluoropyrimidine-based chemotherapy are at increased risk of toxicity. Given the known sex differences in fluoropyrimidine pharmacokinetics, sex-specific dosing of fluoropyrimidines warrants further investigation.

2 August 2019 in JAMA Network Open
Verified
Journal Article
Closed access
PDF file
LRLuai Al Rabadi
Luai Al Rabadi
MLMichael LeBlanc
Michael LeBlanc
TBTaylor Bucy
Taylor Bucy
LELee M. Ellis
Lee M. Ellis
DHDawn L. Hershman
Dawn L. Hershman
CBCharles D. Blanke
Charles D. Blanke
The Oregon Death With Dignity Act, passed in 1994, legally permits terminally ill adults (age ≥18 years) with legal Oregon (OR) residency to make the voluntary informed choice to obtain a physician’s prescription for oral drugs to end life.1 In 2008, Washington state (WA) approved similar legislation, making it the second US state to legalize medical aid in dying (MAID).2 Today, MAID has become more widely adopted and is officially permitted in 8 jurisdictions in the United States (OR [1994], WA [2008], Montana [2009], Vermont [2013], California [2015], Colorado [2016], District of Columbia [2017], and Hawaii [2019]) and will be adopted in New Jersey on August 1, 2019.

1 January 2005 in Cancer Investigation
Verified
Journal Article
Closed access
CBCharles D. Blanke
Charles D. Blanke
CCChristopher L. Corless
Christopher L. Corless
Until recently, there were few effective therapeutic options for patients with gastrointestinal stromal tumors (GISTs). Most patients undergoing even potentially curative resection for early-stage ...

1 November 2001 in Current Treatment Options in Oncology
Verified
Journal Article
Closed access
PDF file
CBCharles D. Blanke
Charles D. Blanke
BEBurton L. Eisenberg
Burton L. Eisenberg
MHMichael C. Heinrich
Michael C. Heinrich